Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of ASP2205 in Healthy Subjects
NCT02314793Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Nov 2014
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP2205 in stress urinary incontinence (SUI) (7 arms), sponsored by Astellas Pharma. Primary endpoints: Safety assessed by nature, frequency and severity of adverse events up to 29 days, Safety assessed by vital signs up to 29 days and 5 more. Started Nov 2014; status: terminated.
02
Drugs
ASP2205
03
Conditions
stress urinary incontinence (SUI)
Beyond the preview
Go deeper on NCT02314793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02314793.